Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)-Gene Rearrangements.
Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)-Gene Rearrangements.
复制标题
DOI：
10.3389/fphar.2021.741413
复制
发表时间：
2021
影响因子：
5.6
通讯作者：
Williams O
中科院分区：
文献类型：
--
作者：
Tsakaneli A;Williams O
混合血统白血病(MLL)基因重排的急性白血病治疗失败率突出表明需要新的治疗方法。考虑到当前治疗方法的局限性和新的药物发现策略的优势，药物再利用为寻找治疗方法和快速有效地开发MLL重排急性白血病的治疗方法提供了宝贵的机会。这些方法是对新药发现的补充，并利用了对MLL-融合蛋白复合体功能的机制基础的更多了解以及改进的药物再用途筛选。尽管存在大量不同的白血病相关MLL重排，但共同的核心致癌途径的存在有望使许多此类治疗方法作为一个整体广泛适用于MLL重排白血病。
The treatment failure rates of acute leukemia with rearrangements of the Mixed Lineage Leukemia (MLL) gene highlight the need for novel therapeutic approaches. Taking into consideration the limitations of the current therapies and the advantages of novel strategies for drug discovery, drug repurposing offers valuable opportunities to identify treatments and develop therapeutic approaches quickly and effectively for acute leukemia with MLL-rearrangements. These approaches are complimentary to de novo drug discovery and have taken advantage of increased knowledge of the mechanistic basis of MLL-fusion protein complex function as well as refined drug repurposing screens. Despite the vast number of different leukemia associated MLL-rearrangements, the existence of common core oncogenic pathways holds the promise that many such therapies will be broadly applicable to MLL-rearranged leukemia as a whole.
登录
查看更多内容
影响因子：
--
作者：
Aguilar-Quesada R;Muñoz-Gámez JA;Martín-Oliva D;Peralta A;Valenzuela MT;Matínez-Romero R;Quiles-Pérez R;Menissier-de Murcia J;de Murcia G;Ruiz de Almodóvar M;Oliver FJ
通讯作者：
Oliver FJ
影响因子：
4.8
作者：
Bode, Guenther;Lueken, Aloys;Nacken, Wolfgang
通讯作者：
Nacken, Wolfgang
影响因子：
4.6
作者：
Bledau, Anita S.;Schmidt, Kerstin;Anastassiadis, Konstantinos
通讯作者：
Anastassiadis, Konstantinos
影响因子：
6.5
作者：
Elliott, Sarah L.;Crawford, Clark;Willmore, Elaine
通讯作者：
Willmore, Elaine
影响因子：
11.8
作者：
Ernst, P;Fisher, JK;Korsmeyer, SJ
通讯作者：
Korsmeyer, SJ